ANNOUNCEMENTS

XVth International Congress of Nephrology and XIth Latin American Congress of Nephrology

The International Congress of Nephrology and XIth Latin American Congress of Nephrology will be held May 2 to 6, 1999, in Buenos Aires, Argentina, with the Argentine Society of Nephrology as host society. The deadline for abstracts is September 22, 1998. For more information, contact the XVth International Congress of Nephrology, Secretariat of the Congress, Ayacucho 937, 10 G, 1111 Buenos Aires, Argentina. Telephone/fax: 54-1-812-1021; e-mail: bayfem@ibm.net.

Medical Education Conference in Nephrology

"Advanced Nephrology: Nephrology for the Consultant," a continuing medical education conference, will be held January 29–31, 1998, at the La Jolla Marriott, La Jolla, California. The conference is sponsored by the Division of Nephrology, Department of Medicine, University of California, San Diego. The course is designated for 17 hours of AMA Category I accreditation. Registration fees are as follows: $425 for physicians in practice, $175 for residents/fellows. For more information, contact Shirley Kolkey, Course Coordinator, 1660 Hotel Circle North, #220, San Diego, CA 92108. Telephone: (619) 299-6673; fax: (619) 299-6675.

Third International Conference on Continuous Renal Replacement Therapies

The Third International Conference on Continuous Renal Replacement Therapies will be held March 5 to 7, 1998, at the Hotel del Coronado in San Diego, California. This international symposium provides a forum for multidisciplinary interactions between physicians, nurses, support personnel, and industry involved in the care of the critically ill patient. The conference focuses on disseminating information on the latest developments and research in the rapidly changing field of ICU medicine and CRRT, with an opportunity for networking and access to international experts from nephrology, critical care, nursing, and industry. Time-efficient instruction methods include: invited lectures; panel discussions; debates; oral and poster presentations; and interactive and hands-on workshops. Major topics to be addressed include: evolving concepts in the management of the critically ill patient; practice of CRRT and standardization of care; renal replacement and renal support; and experience and controversies with CRRT. For information, contact Shirley Kolkey, Complete Conference Management, 1660 Hotel Circle North, #220, San Diego, CA 92108. Telephone: (619) 299-6673; fax: (619) 299-6675; e-mail: c-c-m@worldnet.att.net.

First International Course on Critical Care Nephrology, Vicenza, Italy

The "First International Course on Critical Care Nephrology" will be held May 20–23, 1998, in Vicenza, Italy. Experts in the field of intensive care medicine and nephrology will conduct the course, and the first Vicenza Critical Care Nephrology Award will be given to an eminent scientist in the field. For more information, contact Dr. Claudio Ronco, Department of Nephrology, St. Bortolo Hospital, via Rodolfi, 36100 Vicenza, Italy. Telephone: 39-(0)444-993652; fax: 39-(0)444-920693; e-mail: cronco@goldnet.it.

Third European Peritoneal Dialysis Meeting

The Third European Peritoneal Dialysis Meeting will be held in Edinburgh, Scotland, on April 5–7, 1998. The meeting will focus on maintaining longevity in peritoneal dialysis. The scientific programme will include state-of-the-art lectures and symposia, free communications and poster sessions. There will also be a workshop on animal models in peritoneal dialysis and continuing medical education sessions. The second announcement, call for abstracts, and registration will be sent out in August. Dr. R. I. Winney is the local organizer and can be contacted at the Department of Renal Medicine, Edinburgh Royal Infirmary NHS Trust, Lauriston Place, Edinburgh EH3 9YW Scotland. Telephone: +44-131-536-2305/6; fax +44-131-536-1541; e-mail: R. J. Winney@ed.ac.uk. For further information, please contact Ms. Margaret Sherry, In-Conference Ltd, The Stables, 10B Broughton Street Lane, Edinburgh EH1 2LY Scotland. Telephone: +44-131-556-9245; fax +44-131-556-9638; e-mail: 100256.1750@compuserve.com.

1st International Congress on Immunointervention in Nephrology

The 1st International Congress on Immunointervention in Nephrology, organized by the Department of Nephrology, Ospedale S. Michele, Cagliari, Italy (P. Altieri, M.D.), and the Division of Nephrology, Ospedale Maggiore IRCCS, Milan, Italy (C. Ponticelli, M.D.), will be held April 30–May 2, 1998, in Cagliari, Sardinia, Italy. The meeting will deal with new therapeutic strategies in kidney transplantation and with clinical and therapeutic aspects of lupus nephritis. Tuition is $250. The deadline for abstract presentation is January 15, 1998. For information contact: Paolo Altieri, M.D., Dipartimento di Nefrologia e Dialisi, Ospedale S. Michele, Via Peretti, 09134 Cagliari (Italy). Telephone and fax: ++39-70-542872 or ++39-70-539491.

XVII World Congress of The Transplantation Society

The XVII World Congress of The Transplantation Society will be held July 12–17, 1998, in Montréal, Canada. The deadline for abstracts is January 19, 1998. For information, contact Lucy Felicissimo & Associates, Inc., 12,449 rue Cousineau, Montréal, Quebec, Canada H4K 1P9. Fax: 514-334-5200.

The 25th Annual Seminar in Pediatric Nephrology, "Kidney Disorders in Children: A 25-Year Overview"

The 25th Annual Seminar in Pediatric Nephrology, "Kidney Disorders in Children: A 25-Year Overview," will be held
January 31 through February 4, 1998, at the Fontainebleau Hilton Resort and Spa, Miami Beach, FL. The meeting is sponsored by the Department of Pediatrics, University of Miami School of Medicine. For more information, contact Jose Strauss, Program Chairman and Director, Division of Pediatric Nephrology, University of Miami School of Medicine, P. O. Box 016960, Miami, FL 33101. Phone: (305) 585-6726; fax: (305) 547-1709; e-mail: jstrauss@mednet.med.miami.edu or jstrauss@peds.med.miami.edu.

CME Credit Available for Practicing Nephrologists

Credit hours in Category I of the Physician's Recognition Award of the American Medical Association are available in a course being offered May 3 to 8, 1998, Copley Plaza Hotel, Boston, MA. The course, designed for the practicing nephrologist, will review pathophysiologic and clinical advances in the major areas of nephrology, including glomerular disease, fluid, and electrolyte disorders, hypertension dialysis, and renal transplantation. It is sponsored by the Department of Continuing Education, Harvard Medical School, and the Department of Medicine, Beth Israel Deaconess Medical Center. For more information, contact Professional Meeting Planners, 5 Central Square, Suite 201, Stoneham, MA 02180. Telephone: (781) 279-9887 or 800-378-6857; fax: (781) 279-9875; e-mail: PMPMeeting@aol.com.

Second Meeting of the International Society for Apheresis (ISFA)

The second meeting of the International Society for Apheresis (ISFA) will be held April 15 to 18, 1999, in Saarbrücken, Germany. The ISFA was founded in April 1996 in Kyoto, Japan. The program will include more than 15 main topics. Plenary sessions, symposia, workshops, and oral and poster sessions are planned. Main topics include clinical results, new aspects, immunomodulation in plasmapheresis, selective separation methods, and bioreactors. Costs and benefits of plasmapheresis will also be discussed. For more information, contact Dr. Rolf Bambauer, Congress President, Talstrasse 49, 66424 Homburg/Saar, Germany, Telephone: 06841/2081; fax: 06841/61183.

---

**STATEMENT OF OWNERSHIP MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685)**

1. Publication Title: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
2. Publication no.: 1046-6673
3. Filing date: 10-01-97
4. Frequency of issue: Monthly
5. No. of issues published annually: 13
6. Annual subscription price: $265.00
7. Complete mailing address of known office of publication: 351 West Camden Street, Baltimore, MD 21201-2436
8. Complete mailing address of the headquarters of general business offices of the publisher: 351 West Camden Street, Baltimore, MD 21201-2436
9. Full names and complete mailing address of publisher, editor, and managing editor: Publisher: Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436; Editor: C. Craig Tisher, M.D., Division of Nephrology, Hypertension and Transplantation, Box 100224 JHMC, 1600 SW Archer Road, University of Florida, Gainesville, FL 32610-0224; Managing Editor: Bonnie O'Brien, Division of Nephrology, Hypertension and Transplantation, Box 100224 JHMC, 1600 SW Archer Road, University of Florida, Gainesville, FL 32610-0224
10. Owner: American Society of Nephrology, Judith A. Thomas, Executive Director, 1200 19th Street, N.W., Suite 300, Washington, DC 20036-2401
11. Known bondholders, mortgagees, and other security holders owning or holding 1% or more of total amount of bonds, mortgages, or other securities: None.
12. Purpose, function, and nonprofit status: Has not changed during preceding 12 months.
13. Publication Name: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
15. Extent and nature of circulation: Average number of copies each issue during preceding 12 months: (a) Total No. copies (Net Press Run), 8,033. (b) Paid and/or requested circulation: (1) Sales through dealers and carriers, street vendors and counter sales (not mailed), 411; (2) Paid or Requested mail subscriptions (include Advertisers Proof Copies/Exchange Copies), 6,485. (c) Total paid and/or requested circulation (sum of 15b(1) and 15b(2)), 6,896. (d) Free distribution by mail (samples, complimentary, and other free copies), 428. (e) Free distribution outside the mail (carriers or other means), none. (f) Total free distribution (sum of 15d and 15e), 428. (g) Total distribution (Sum of 15d and 15f), 7,292. (h) Copies not distributed: (1) Office use, leftovers, spoiled, 741; (2) Return from news agents, none. (i) Total (sum of 15g, 15h(1), and 15h(2)), 8,033. Percent Paid and/or Requested Circulation (15c/15g x 100) 94.16%. Actual No. copies of single issue published nearest to filing date: (a) Total no. copies (Net Press Run), 8,198. (b) Paid and/or requested circulation: (1) Sales through dealers and carriers, street vendors and counter sales (not mailed), 506; (2) Paid or Requested mail subscriptions (include Advertisers Proof Copies/Exchange Copies), 6,553. (c) Total paid and/or requested circulation (sum of 15b(1) and 15b(2)), 7,059. (d) Free distribution by mail (samples, complimentary, and other free copies), 450. (e) Free distribution outside the mail (carriers or other means), none. (f) Total free distribution (sum of 15d and 15e), 450. (g) Total distribution (Sum of 15c and 15f), 7,509. (h) Copies not distributed: (1) Office use, leftovers, spoiled, 689; (2) Return from news agents, none. (i) Total (sum of 15g, 15h(1), and 15h(2)), 8,198. Percent Paid and/or Requested Circulation (15c/15g x 100), 94.0%.
16. This Statement of Ownership will be printed in the December issue of this publication.
17. I certify that the statements made by me above are correct and complete.

Alma J. Wills
Publisher
ACKNOWLEDGMENT OF MANUSCRIPT CONSULTANTS

JASM VOLUME 8

The success of the Journal is predicated in large part on our ability to obtain timely reviews of high quality from our referees. The editorial staff publicly acknowledges with gratitude the individuals listed below who have participated in the review process during the past 15 months.

C. Craig Tisher, M.D.
Editor

Abbildung, Patricia L.
Abbildung, Hanni
Abraham, Paul
Abrahamson, Dale
Abramovitz, Joel
Abramovicz, Daniel
Acchiardo, Sergio
Adams, John
Agarwal, Anupam
Agre, Peter
Alpers, Charles
Anderson, Robert
Anderson, Sharon
Andrassy, Konrad
Andres, Giuseppe
Anse Marahk-Rothstein
Antignac, Corinne
Appel, Gerald
Arendt, William
Ash, Stephen
Atkins, Robert
Atman, Per-Ola A.
Avner, Ellis
Avram, Morrel M.
Aziz, Nazneen
Baccaloo, Robert
Bachmann, Sebastian C.
Badr, Kamal
Baines, Andrew
Bakris, George
Balow, James
Bankir, Lise
Barajas, Luciano
Baricu, William
Battie, Daniel
Baum, Laurent
Baum, Michel
Baylis, Christine
Beachard, Gerald
Becker, David
Beierwaltes, William
Bell, P. Darwin
Benigni, Ariela
Bennett, William
Berd, Thomas
Berliner, Judith
Bernstein, Jay
Bernstein, Kenneth
Besarab, Anatole
Better, Ori S.
Bichet, Daniel B.
Bienenberger, Daniel R.
Blagg, Christopher
Blake, Peter
Blankeship, Peter J.
 Blickman, Johan
Blon, Edward R.
 Bolton, Kline
Bommer, Jurgen
Bonventre, Joseph
Bosch, Juan
Boston, Andrew
Bourgoignie, Jacques
Braun, William E.
Brennan, Daniel
Breislaw, Neil A.
Breuning, Martin
Breyer, Julia
Breyer, Matthew
Brinker, Karl
Brown, Dennis
Brown, Gail P.
Brugnara, Carlo
Bruijna, Jan A.
Buckalew, Vardaman

Burke, Thomas
Burnett, John C. Jr.
Burns, Kevin D.
Bushinsky, David
Caligiuri, Michael A.
Calvert, James P.
Cambien, F.
Campese, Vito
Caramelo, Carlos
Carmignani, Pamela
Cattell, Victoria
Cendoroglo, Miguel
Chaimovitz, Chidio
Chan, Laurence
Chao, Julie
Chapman, Arlene
Charles B. Carpenter
Chertow, Glen
Cheesley, Russell
Chin, Edward
Chonko, Arnold
Christensen, Erik Ilse
Churchill, David
Clapp, William M.
Clark, William F.
Clark, William R.
Coburn, Jack
Coffman, Thomas
Coggins, Michael
Cohen, Margo
Collins, Allan
Colvin, Robert
Comper, Wayne
Cong, John D.
Coote, J.H.
Corper, Cindy
Cortese, Pedro
Cosio, Fernando
Cotran, Genie L.
Couder, William G.
Cowley, Benjamin
Croker, Byron P.
Crosby, Robert
Curto, John
D’Amico, Giuseppe
Daha, Mohamed R.
Daniel, Thomas
Daniels, Barbara S.
Danoff, Theodore
Daugirdas, John T.
Davies, Malcolm
Davidson, Alex
De Broe, Marc E.
De Rouffignac, Christian P.
De Simone, Giovanni
Dees, William T.
Delmez, James A.
Denhardt, David
Dennis, Vincent
Deppe, Thomas
Descamps-Latscha, Beatrice
Diamond, Jonathan R.
Diaz-Buxo, Jose
Dibernam, Arnold G.
Dixon, Bradley S.
Dox, Burl
Donadio, James V.
Douglas, Janice
Douglas, Thomas
Drucke, Tilman
Druml, Wilfred
DuBois, Susan
Dumler, Francis
Durr, Jacques A.
Dwarkin, Lance
Eddy, Allison
Edelson, Richard
Eggers, Paul
Egido, Jesus
Eknoyan, Gary
Ellison, David
Emancipator, Steven
Evans, Andrew
Fadok, Valerie
Falk, Ronald J.
Farman, Nicolette
Fecaulty, John
Feld, Leonard G.
Felsenfeld, Arnold
Fernandez-Pedro
Finn, William
First, M. Roy
Flamion, Bruno
Flanigan, Michael John
Floge, Jurgen
Flyvberg, Allan
Fogo, Agnes
Foley, Robert
Forbush, Bliss
Forsmann, W.G.
Frasch, Harold A.
Freedman, Barry
Freedman, Dilies
Friedlander, Miriam
Friedman, Elia A.
Funder, John
Gabow, Patricia
Gaffet, Uzi
Galle, Jan
Ganz, Michael
Gardner, Kenneth
Garroyo, Marvins
Garin, Jeffrey L.
Gaspare, Flavio L.
Gaston, Robert S.
Gattone, Vincent
Genrani, F. John
Genro, Gregory
Geske, Frank
Giebisch, Gerhard
Gitelman, Hillel
Giomero, William
Glassock, Richard
Glicklich, Daniel
Gobe, Glenda C.
Goldblatt, Peter
Goldstein, Mark B.
Golper, Thomas
Goodman, Timothy
Goot, Frank
Gotschall, Robert
Grönhagen-Riska, Carla
Grande, Joseph P.
Grant, Maria
Greene, Tom
Guay-Woodford, Lisa
Guzman, Nicholas
Hörter, Walter H.
Haus, Mark
Haefner-Cavaill, Nicole
Haines, Jonathan L.
Hakim, Raymond M.
Hall, Dallas
Hall, Hermann
Halperin, Mitchell
Hamburger, Richard J.
Hamm, L. Lee
Hammerling, Ulrich
Hammerman, Marc

Hendler, Joseph
Harris, Peter
Harris, Roy
Habert, Lee
Heinburger, Olof
Helderman, J. Harold
Helmchen, Ucko
Henrich, William
Hess, Bernard
Hikif, Yoshihiko
Hill, Kapturczak, Nathalie
Hillis, L. David
Himmelfarb, Jonathan
Hirschberg, Raimond
Hirsh, Richard
Hise, Michael
Hogg, Ronald
Holguin, Mark
Hollenhagen, Norman
Holmes, Clifford J.
Holzman, Lawrence
Horie, Shigeo
Hossetter, Thomas
Hoyer, R.
Hrick, Donald
Hughes, Jeremy
Humes, H. David
Humphreys, Michael
Hunsicker, Lawrence
Ichikawa, Ikuki
Ikizler, Alp
Imai, Erdik
Ing, Todd
Inscho, Edward
Ivanovich, Peter
Jardine, Alan
Jennette, Charles
Jerums, George
Johnson, Richard
Joles, John A.
Jones, Michael R.
Jorge, Anch
Jospe, Pedro
Joyner, Michael J.
Julian, Bruce
Jupner, Harald
Kahan, Barry
Kaisling, Brigitte
Kishore, B.K.
Kamanna, Vijay S.
Kanwar, Yashpal
Kaplan, Andre
Kapurczak, Mattias
Karet, Fionia
Kashlan, Clifford
Kasirke, Bertram L.
Kassel, Frederick
Kassab, Saleh
Kaysen, George
Kazakhstan, Michel
Keane, William
Kelly, Carolyn
Kelly, Ralph
Kempson, Stephen
Keryaschi, R.
Khans, Saeed
Khanna, Ramesh
Khraib, Ali A.
Kikawa, Yachi
Kimmel, Paul
Kimura, Kenjiro
King, Andrew J.
King, Greg L.
Kirsch, B.K.
Kitamura, Kenichiro
<table>
<thead>
<tr>
<th>Author</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weaver, C., 1930</td>
<td></td>
</tr>
<tr>
<td>Weber, A., 1319</td>
<td></td>
</tr>
<tr>
<td>Weening, J. J., 249</td>
<td></td>
</tr>
<tr>
<td>Weinberg, J., 689</td>
<td></td>
</tr>
<tr>
<td>Weiner, I. D., 1179</td>
<td></td>
</tr>
<tr>
<td>Weinstein, T., 586, 1579</td>
<td></td>
</tr>
<tr>
<td>Weiss, M., 1930</td>
<td></td>
</tr>
<tr>
<td>Weiss, R. H., 1247</td>
<td></td>
</tr>
<tr>
<td>Wetzel, J. F. M., 706</td>
<td></td>
</tr>
<tr>
<td>Werer, P. C., 1517</td>
<td></td>
</tr>
<tr>
<td>Wibers, D. O., 1298</td>
<td></td>
</tr>
<tr>
<td>Wiggins, R., 1018</td>
<td></td>
</tr>
<tr>
<td>Wilcox, C., 1018</td>
<td></td>
</tr>
<tr>
<td>Willett, W. C., 1568</td>
<td></td>
</tr>
<tr>
<td>Williams, D. L., Jr., 1061</td>
<td></td>
</tr>
<tr>
<td>Williams, J. D., 604</td>
<td></td>
</tr>
<tr>
<td>Wilson, C. B., 1174</td>
<td></td>
</tr>
<tr>
<td>Wilson, D. M., 1283</td>
<td></td>
</tr>
<tr>
<td>Windus, D. W., 1315</td>
<td></td>
</tr>
<tr>
<td>Wingo, C. S., 1179</td>
<td></td>
</tr>
<tr>
<td>Winyard, P. J. D., 1647</td>
<td></td>
</tr>
<tr>
<td>Wish, J. B., S1</td>
<td></td>
</tr>
<tr>
<td>Witzgall, R., 1213</td>
<td></td>
</tr>
<tr>
<td>Wolf, G., 551</td>
<td></td>
</tr>
<tr>
<td>Wolff, J., 214</td>
<td></td>
</tr>
<tr>
<td>Wood, W. M., 1863</td>
<td></td>
</tr>
<tr>
<td>Woolf, A. S., 1647</td>
<td></td>
</tr>
<tr>
<td>Wright, J., 279</td>
<td></td>
</tr>
<tr>
<td>Wu, J., 1072</td>
<td></td>
</tr>
<tr>
<td>Wu, L. L., 1373</td>
<td></td>
</tr>
<tr>
<td>Wu, X-H., 1072</td>
<td></td>
</tr>
<tr>
<td>Wühl, E., 242</td>
<td></td>
</tr>
<tr>
<td>Yamada, T., 51, 817</td>
<td></td>
</tr>
<tr>
<td>Yamaguchi, J., 1164</td>
<td></td>
</tr>
<tr>
<td>Yamamoto, T., 1174</td>
<td></td>
</tr>
<tr>
<td>Yaoita, E., 1174</td>
<td></td>
</tr>
<tr>
<td>Yip, J., 1133</td>
<td></td>
</tr>
<tr>
<td>Yoshida, K., 260</td>
<td></td>
</tr>
<tr>
<td>Yosipiv, I. V., 920</td>
<td></td>
</tr>
<tr>
<td>Yu, L., 1415</td>
<td></td>
</tr>
<tr>
<td>Yumura, W., 580, 1399</td>
<td></td>
</tr>
<tr>
<td>Yuzawa, Y., 1363</td>
<td></td>
</tr>
<tr>
<td>Zachem, C. R., 1838</td>
<td></td>
</tr>
<tr>
<td>Zadeii, G., 1034</td>
<td></td>
</tr>
<tr>
<td>Zanello, F., 1147</td>
<td></td>
</tr>
<tr>
<td>Zappia, V., 1899</td>
<td></td>
</tr>
<tr>
<td>Zayas, C. F., 793</td>
<td></td>
</tr>
<tr>
<td>Zevin, D., 1579</td>
<td></td>
</tr>
<tr>
<td>Zhang, L., 1043</td>
<td></td>
</tr>
<tr>
<td>Zhao, H., 193</td>
<td></td>
</tr>
<tr>
<td>Zhou, W., 214</td>
<td></td>
</tr>
<tr>
<td>Zhou, X-J., 901</td>
<td></td>
</tr>
<tr>
<td>Zhu, F-Y., 777</td>
<td></td>
</tr>
<tr>
<td>Ziyadeh, F. N., 551</td>
<td></td>
</tr>
<tr>
<td>Zoccali, C., 1574</td>
<td></td>
</tr>
<tr>
<td>Zoja, C., 720</td>
<td></td>
</tr>
<tr>
<td>Zou, L-X., 535</td>
<td></td>
</tr>
</tbody>
</table>
Absorption
homologous albumin, proximal tubule cell (rat), 323
peritoneal fluid, hyaluronan decreases, 1915
Acetate intolerance, nitric oxide synthesis mediation, endothelial cell, 1431
Acetylcysteine, cisplatin-induced renal toxicity treatment, 1640
Acid loading, acute, IMCD 11\(\beta\)-hydroxysteroid dehydrogenase type 2 inhibition by, 530
Acid secretion, adaptive increase, remnant kidney (rat), 868
Acidification, renal, acute oral protein load (human), 784
Acidosis
calcium sensitivity of parathyroid glands, hemodialysis patients, 627
coma with, posthemodialysis, 853
distal renal tubular, hyperkalemic, 1109
hemodialysis, whole-body protein degradation, 632
metabolic, orthotopic ileal neobladder, 1553
Acquired immunodeficiency syndrome, Kaposi’s sarcoma, posttransplant immunosuppression, 130
Activationsympathetic nervous system, early essential hypertension, 893
Acyclovir, nephrotoxicity, glomerular hemodynamics (rat), 361
Ad hoc committee report, future workforce estimation and training requirements, nephrology, S1
Adenovirus vector, cell cycle inhibitor overexpression, mesangial cell proliferation regulation, 51
Adenylate cyclase activity, nephron isolated segments, rabbit, 1608
Adequacy of dialysis
decreasing, 1315
increasing dialysis volume affecting, 1304
Adhesion, tubular cell, \(\beta\) integrin-mediated (murine), 175
Adolescence
hypokalemia and metabolic alkalosis, cystic fibrosis presentation, 352
transplantation during, recurrent vascular thrombosis, 1477
ADPKD: see Polycystic kidney disease, autosomal dominant
African Americans
hypertensive nephrosclerosis, glomerular filtration rate estimation, serum creatinine, 279
non-insulin-dependent diabetes mellitus and nephropathy, proteinuria in, 793
African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study, glomerular filtration rate estimation, serum creatinine, 279
Agonist, calcium regulation induced by, renal microvascular smooth muscle cells (rat), 569
AIDS: see Acquired immunodeficiency syndrome
Albumin, homologous, proximal tubule cell absorption (rat), 323
Albuminuria, vitamin C or E effects, diabetes (rat), 1405
Aldosterone, synthesis rate affected by, epithelial sodium channel \(\alpha\) subunit, 1813
Alkalosis, metabolic, 1462
cystic fibrosis presenting with, 352
Allograft, renal: see also Transplantation, kidney
glomerular injury in, 1801
intrarenal Doppler indices, 813
survival, 1319, 1771
Aluminum uptake, hepatocyte, p-cresol enhancement (murine), 935
American Heart Association, Kidney Council, editorial, 1624
American Society of Pediatric Nephrology, Workforce Committee, future workforce needs, S5
Amiloride, sodium channel \(\beta\) subunit sensitive to, gene expression, 126
Amino acid, varying levels, protein metabolism affected by (rat), 1399
Aminonucleoside
nephrosis, chronic puromycin (rat), 1383
puromycin, nephrotic syndrome induced by, 15
Aminopeptidase A, glomerular epithelial cell expression, culture (murine), 706
Amphotericin B, nephrotoxicity, lipid emulsion solubilization attenuation (rat), 1415
Amyloidosis
dialysis-related, advanced glycation end products in (rodent), 260
\(\beta\)-2-microglobulin, chronic dialysis patients, 509
ANCA: see Anti-neutrophil cytoplasmic autoantibodies
Anemia in the hemodialysis patient
low-dose subcutaneous erythropoietin in, 288
outcome prediction, 1921
Aneurysm
intracranial, polycystin expression, 616
saccular, intracranial arterial dolichoectasia mimicking, 1298
Angiotensin II
calcium mobilization, nephrin (rat), 1658
hypertension induction, \(\text{AT}_1\) receptor blockade renal responses (rat), 535
nitric oxide synthase inhibition, tubular MCT cells, 551
nitric oxide synthesis inhibition, renal effects, 543
proteinuria induced by, platelet-activating factor mediates (rat), 1391
TGF-\(\beta\) interaction with, remnant kidney (rat), 1732
Angiotensin II receptor, proximal tubule, expression regulation, 306
Angiotensin type 1 receptor, regulation and gene expression, renal growth related to, 193
Angiotensin-converting enzyme
genotype, renal allograft survival, 1319
inhibition
chronic renal damage treated by (rat), 249
endothelin-1 expression and synthesis (rat), 756
nephropathy, HIV-associated, 1140
Angiotensigen
gene expression, cAMP-responsive element binding protein stimulation (opossum), 1072
glomerular epithelial cell expression, culture (murine), 706
Anion
endogenous and xenobiotic, secretion, 1213
organic secretion, polycystic kidney disease (rat), 1222
Anionic
compound, polyaromatic, heparin-mimicking, 1688
Antigen
anti-glomerular basement, sera with or without antineutrophil cytoplasmic antibodies, 376
anti-monoocyte chemoattractant protein-1, anti-glomerular basement membrane nephritis suppression (rat), 1174
Antigen
anti-neutrophil cytoplasmic antibody crosslinking, neutrophil superoxide release stimulation (human), 386
Goodpasture, conformation epitope, 1698
staphylococcal, bacterial infection and glomerulonephritis pathogenesis, 1633
Antigen specificity, anti-glomerular basement membrane antibodies, sera with or without antineutrophil cytoplasmic antibodies, 376
Antigen-antibody complex, complement component C3 production enhancement, mesangial cell (human), 1257
Antigenemia, cytomegalovirus infection, renal transplantation, 1448
Antihypertensive therapy, creatinine clearance and serum creatinine concentration affected by, erratum, 1354
Anti-neutrophil cytoplasmic antibody
antigen crosslinking, neutrophil superoxide release stimulation (human), 386
sera with or without, anti-glomerular basement membrane antibodies in, 376
Anti-neutrophil cytoplasmic autoantibodies, vasculitis with, small-vessel, 314
Antioxidant
reactive oxygen species and, puromycin aminonucleoside glomerulopathy, 1722
renal injury prevention, diabetes, 1405
serum, hemodialysis increasing, 1157
Antiproliferative activity, glomerular mesangial cell, 1688
cystic diseases, epithelial galectin-3 in, 1647
minimal change nephrotic syndrome, prognostic significance of early course, 769
Chondroitin sulfate, tubular epithelium distribution, renal (rat), 586
Cisplatin
nephrotoxicity, clusterin temporal induction (rat), 302
renal toxicity induced by, acetylcysteine treatment, 1640
CIL100, mesangial cell, differential regulation, 40
Clusterin, temporal induction, cisplatin nephrotoxicity (rat), 302
Clusterin mRNA, thrombin increasing, glomerular epithelial and mesangial cells (rat), 906
Clustering, familial, end-stage renal disease, 1942
Collagen, type IV, antisense inhibition, 61
Collagen synthesis, cultured skin fibroblasts, insulin-dependent diabetic patients with nephropathy, 1133
Collagenase, type IV, matrix metalloproteinase inhibition (rat), 395
Collecting duct, inner medullary
11β-hydroxysteroid dehydrogenase type 2, 530
terminal (rat), 517
Coma, acidosis with, posthemodialysis, 853
Complement
injury mediated by, mesangial cell, Crry overexpression for protection (rat), 223
tubulointerstitial lesion pathogenesis, mesangial proliferative glomerulonephritis (rat), 1363
Complement C3, renal cortical, gene expression in IgA nephropathy, 415
Complement C4, renal epithelium synthesis, passive Heymann nephritis (rat), 214
Complement component C3
production of, antigen-antibody complexes enhance, 1257
renal inflammation, IL-2 receptor regulation, 1510
Complication
neurologic, hyponatremia, 1599
parathyroid surgery, hungry bone syndrome, 1626
Composition, body, peritoneal dialysis patient, 1906
Computer-based model, renal replacement therapy, acute renal failure, 804
Concentration, urinary, micropuncture study of, 153
Constriction, afferent arteriole, thromboxane mimetic U44069, 25
Converting enzyme inhibition, proteinuria affected by, African Americans with NIDDM and nephropathy, 793
Cooling, blood, controlled extracorporeal, 957
Coronary artery disease, prediction, hemodialysis patients, 1889
Cost, hemodialysis patients, low-dose subcutaneous erythropoietin in, 288
Cost-effectiveness, mycophenolate mofetil, posttransplantation, 1592
Costa Rica, Barter’s syndrome in, NKCC2 mutation, 1706
Cox proportional hazards model, risk ratio calculation, 1560
Creatinine, serum, glomerular filtration rate estimation, African Americans with hypertensive nephrosclerosis, 279
P-Cresol, aluminum uptake enhancement, hepatocyte (murine), 935
Cross-clamping, aortic, dual ETA/ETB endothelin antagonist renal protection (dog), 1061
Crosslinking, ANCA-antigens, neutrophil superoxide release stimulation (human), 386
Cry overexpression, complement-mediated injury protection, mesangial cell (rat), 223
Cryoglobulinemia, type III essential mixed, subacute bacterial endocarditis masquerading as, 1971
Culture, skin fibroblasts, insulin-dependent diabetic patients with nephropathy, 1133
Curriculum
core, nephrology, 1019
nephrology, editorial, 1016
Cyclic adenosine monophosphate
aquaporin-2 water channel gene regulation, transcriptional (murine), 861
nitrergic oxide synthase and calcium influx inhibition, renal epithelial cells, 558
Cyclin, glomerular expression, remnant, 368
Cyclin D1, overexpression, mesangial cell proliferation regulation, 51
Cyclosporine
area under the curve prediction, three-point sampling strategy, 647
kidney transplant patients, late prednisone withdrawal, 294
renal transplantation, cadaveric, 638
Cyst, renal, 1222
Cysteine, secreted protein rich in, subtotal nephrectomy preceding (rat), 1374
Cystic disease, childhood, epithelial galectin-3 in, 1647
Cystic fibrosis, hypokalemia and metabolic alkalosis presentation, previously healthy adolescent, 352
Cytokines
apoptosis regulation, renal interstitial fibroblasts (murine), 1845
high-flux dialysis, 1745
Cytomegalovirus
glomerular injury caused by, renal allograft recipients, 1801
infection, renal transplantation, monitoring and diagnosis, 1448
morbidity, renal transplant patients, 118
Danaparoid sodium, proteinuria lowered by, diabetic nephropathy, 456
Death, dialysis withdrawal before, risk factors, 1755
Deficiency, nitric oxide, chronic, 1125
Deoxycytidine monophosphate
cyclical, antisense, procollagen α1(IV), 61
hepatitis B virus, hemodialysis patients, 1443
mitochondrial, mutation, 1118
Diabetes
glomerular dysfunction, d-α-tocopherol prevention (rat), 426
GLUT2 gene overexpression, renal proximal tubules (rat), 943
insulin-dependent, nephropathy with, 1133
nephropathy, proteinuria in, 456
renal hypertrophy, insulin-like growth factor I accumulation (mice), 436
vitamin C or E supplementation (rat), 1405
Diabetes insipidus
hypothalamic, familial (rat), 1333
nephrogenic
AQP2 gene mutation, 242
congenital, 1855, 1951
Diabetes mellitus
early, sodium restriction (human), 749
non-insulin-dependent, African Americans with, 793
Diagnosis, cytomegalovirus infection, renal transplantation, 1448
Dialysate
acetate-free, 1431
calcium concentration, secondary hyperparathyroidism, 993
low calcium, CAPD patients, 1579
Dialysis: see also Hemodialysis
acute renal failure, mortality prediction, 111
chronic, β2-microglobulin amyloidosis, 509
high-flux, cytokine profiles during, 1745
incident, end-stage renal disease family history among, 1942
increasing volume, adequacy targets affected by, 1304
nitrergic oxide inhibitor, endogenous, 1437
parathyroid hormone plasma concentration, volume depletion and central hypovolemia influencing, 1574
peritoneal: see Peritoneal dialysis
protein intake, dietary, 777
withdrawal before death, risk factors, 1755
Dialyzer
artificial kidney, 1959
circuit, calcitriol removal, 1587
Diet
calcium restriction, kidney stone risk, 1568
creatinine clearance and serum creatinine concentration affected by, erratum, 1354
low electrolyte, 524
protein intake, renal disease, 777
Differential regulation, protein-tyrosine phosphatases, dual-specificity, mesangial cell, 40
Differentiation
podocyte, cultured rat and human, 697
renal, urinary tract obstruction, 653
Dimethylarginine, serum levels, dialysis patients, 1437
Diuresis
atrial natriuretic peptide, renal patients, 445
osmotic, 153
mannitol-induced, 1028
Dolichosibotasia, arterial, intracranial, 1298
Dopaminergic system, proximal tubule, 306
Doppler indices, intrarenal, stable renal allografts, 813
Downregulation, glucocorticoid, vasopressin-regulated urea transporter (rat), 517
Dysplasia, multicystic renal, insulin-like growth factor gene expression, 85
Edema
cerebral, risk factors, 1599
idiopathic nephrotic syndrome, pathophysiology, 824
Editorials
estimating workforce and training requirements for nephrologists through the year 2010: pediatric perspectives, 846
Kidney Council of the American Heart Association needs support, 1624
lipoprotein glomerulopathy: a new role for apolipoprotein E?, 840
1996 nephrology curriculum: American Society of Nephrology, 1016
Nephrology Manpower Study: what does it mean and what do we do now?, 843
winds of change, 165
Electrolyte excretion, familial hypothalamic diabetes insipidus (rat), 1333
Electron microscopic autoradiography, homologous albumin absorption, proximal tubule cell (rat), 323
Electron microscopy, renal biopsy, native, 70
Electron spin resonance, serum antioxidant activity shown by, hemodialysis patients, 1157
Embolism, pulmonary, thrombolysis of hemodialysis grafts preceding, 1458
Encephalopathy, hepatic, 1179
End products, glycation: see Glycation end products
Endocarditis, bacterial, subacute, 1971
Endocytosis, cell biology, 323
Endothelial cell
glomerular
endothelin-converting enzyme expression, 580
proliferation, 61
nitric oxide synthesis, acetate intolerance mediated by, 1431
Endothelialitis, renal allograft rejection with, 1930
Endothelin
dual ET$_A$/ET$_B$ antagonist, renal protection by, 1061
enzymes converting, glomerular endothelial cells, 580
hypertension associated with, ET$_A$, receptor blockade prevention (rat), 1054
plasma, erythropoietin-induced hypertension not mediated by (rat), 901
prostaglandin endoperoxide synthase mRNA expression induction, mesangial cell (rabbit), 1080
receptor subtypes, endothelin-1 systemic and renal responses, 32
renal expression and synthesis, quinapril decreasing (rat), 756
Enzyme
angiotensin-converting: see Angiotensin-converting enzyme converting, inhibition of, 793
endothelin-converting, glomerular endothelial cells, 580
Epithelial cell
glomerular
renin-angiotensin system component expression (murine), 706
thrombin increases clusterin mRNA (rat), 906
renal, nitric oxide synthase and calcium influx inhibition, 558
tubular, proximal, 184
Epithelium
cystic, proximal, 1222
galecin-3, nephrogenesis and childhood cystic diseases, 1647
renal, complement C4 synthesis, passive Heymann nephritis (rat), 214
sodium channel
amiloride-sensitive, 126
blood pressure control, 980
sodium channel $\alpha$ subunit, renal cells, 1813
tubular: see Tubular epithelium
Epiotope, B cell, mapping of, 1698
Errata
aquaporin-1 water channel expression, 358
diet and antihypertensive therapy effects on creatinine clearance and serum GB creatinine concentration, 1354
dietary protein restriction affecting moderate renal disease progression, 493
Erythrocyte, membrane proteins, D-aspartate content, 95
Erythropoietin
fistula stenosis affected by, hemodialysis patients, 1147
hypertension induced by, mediation of (rat), 901
subcutaneous, low-dose, hemodialysis patients, 288
Estimation, future workforce, nephrology, S1
Estrogen replacement, hypoalbuminemia, atherosclerotic risk enhancement, 1870
ET$_A$/ET$_B$ endothelin antagonist, renal protection by, aortic cross-clamping (dog), 1061
ET$_A$ receptor blockade, hypertension prevention, exogenous endothelin-1 associated (rat), 1054
Ethylene glycol, dialysate solution contamination, acidosis and coma after, 853
Exchanger, urinary, aquaporin-2 water channel protein (human and rat), 1357
Export pump, conjugate, m Epstein gene encoding, 1213
Extracellular matrix
enhanced production, genetic predisposition (rat), 406
excessive deposition of, renal fibrosis (murine), 1845
Extracorporeal therapy, acute renal failure, computer-based model, 804
Family history
end-stage renal disease, incident dialysis patients, 1942
kidney stone risk, 1568
Fas
apoptosis regulation, renal interstitial fibroblasts (murine), 1845
tubular epithelial cell expression, renal (human), 1517
Fat, body, serum immunoreactive leptin concentration related to, 1423
Feedback, tubuloglomerular, luminal potassium, 1831
Fetus, urinary tract obstruction, 653
Fibrogenin, phenotype of, coronary artery disease prediction, 1889
Fibroblast
cortical, normal (human), 604
interstitial, renal (murine), 1845
skin, cultured, 1133
Fibrosis
cystic: see Cystic fibrosis
retroperitoneal, obstructive nephropathy due to, 684
Fish oil therapy, IgA nephropathy, efficacy and interstudy variability, 1739
Fistula, stenosis, hemodialysis, 1147
Fluid accumulation, cyst, renal, 1222
Fluid balance, familial hypothyroidism diabetes insipidus (rat), 1333
FMLP: see Formyl-methionyl-leucyl-phenylalanine
Folate, hyperhomocysteinemia reduction induced by, metabolic consequences, 1899
Formyl-methionyl-leucyl-phenylalanine, apoptosis mediated by, neutrophil superoxide release required for, 1091
Founder effect, Costa Rican Barter’s syndrome, NKCC2 mutation, 1706
Galecin-3, epithelial, nephrogenesis and childhood cystic diseases, 1647
Garcinolivir, nephrotoxicity, glomerular hemodynamics (rat), 361
GB virus C infection, pretransplantation, outcome affected by, 1164
Gender, nitric oxide, renal medullary synthesis influenced by (rat), 1240
Gene expression
m Epstein gene, conjugate export pump encoded by, 1213
amiloride-sensitive sodium channel $\beta$ subunit, B lymphocytes (human), 126
angiotensin type 1 receptor, renal growth related to, 193
angiotensinogen, cAMP-responsive element binding protein stimulation (opossum), 1072
AQP2, nephrogenic diabetes insipidus, 242
AVP, wild-type and Brattleboro rats, 1863
complement C3, renal cortical, gene expression in IgA nephropathy, 415
GLUT2 gene, renal proximal tubules of diabetic Zucker rats, 943
insulin-like growth factor, multicystic renal dysplasia, 85
matrix protein, platelet-activating factor stimulation, 1266
iRNA-related mutation, progressive kidney disease, 1118
Gene linkage analysis, autosomal dominant polycystic kidney disease, 105
Gene polymorphism, vitamin D receptor, hypoparathyroidism associated with, 1546
Genetics
aquaporin-2 water channel gene regulation, transcriptional (murine), 861
diabetic nephropathy, 487
extracellular matrix production, glucose-enhanced (rat), 406
glomerulocystic kidney disease, dominantly transmitted, 77
Genotype, angiotensin-converting enzyme, renal allograft survival, 1319
Glomerular basement membrane
anti-GBM antibodies, 376
anti-GBM disease, Wegener’s granulomatosis with, 1795
anti-GBM glomerulonephritis, humorally mediated injury, 1101
anti-GBM nephritis, anti-monocyte chemotactant protein-1 antibody suppression (rat), 1174
Glomerular disease, tumor-associated glomerulonephritis, unusual, 848
Glomerular dysfunction, d-a-tocopherol prevention, diabetic rats, 426
Glomerular filtration rate
mild renal failure (rat), 271
protein load increasing, acute oral (human), 784
serum creatinine estimation, African Americans with hypertensive nephro-
- sclerosis, 279
single nephron, ultrafiltration coefficient calculation (rat), 833
Glomerular-hemodynamics, nephrotoxicity, acyclovir and ganciclovir (rat), 361
Glomerular hypertrophy, reversible, primary focal segmental glomeruloscle-
rosis with, 1668
Glomerular injury, cytomegalovirus causing, renal allograft recipients, 1801
Glomerulitis, renal allograft rejection with, 1930
Glomerulocystic kidney disease, dominantly transmitted, distinct genetic en-
tity, 77
Glomerulomegaly, proteinuria with, idiopathic pulmonary hypertension, 1966
Glomerulonephritis: see also Immunoglobulin A nephropathy; Nephritis
activated mesangial cells in, B1-integrin expression (human), 1679
anti-glomerular basement membrane, humorally mediated injury, 1101
crescentic, pauci-immune, 70
diffuse proliferative, osteomyelitis with, 1633
decoraditis and, 1781
IL-4 involvement, human, 730
immune complex
complement-dependent model, 214
neutrophil and platelet infiltration in, 1838
lupus, prednisone treatment, 1188
membranous, 664
proliferative, mesangial (rat), 1363
streptococcal, IL-8 and TGF-β immunohistochemical localization, 234
nephropathy, unusual, 848
Glomerulopathy
cytomegalovirus, renal allograft recipients, 1801
lipoprotein
apolipoprotein E Sendai with (human), 820
apolipoprotein E’s role, editorial, 840
puromycin aminonucleoside: see Puromycin aminonucleoside glomerulopa-
thy
Glomerulosclerosis
diabetic, nitric oxide production inhibition (rat), 1276
focal segmental
electron microscopy, 70
idiopathic nephrotic syndrome, 824
primary, 1668
initiation mechanism, pro sclerotic responses (rat), 1525
Glomerulus
hyperfiltration, sympathetic nervous system activation, 893
oxidative stress, 1722
platelet-derived growth factor and PDGF receptor mRNA expression, IgA nephropathy, 817
remnant, cyclin and cyclin-dependent kinase expression in, 368
size, vitamin C or E effects (rat), 1405
ultrafiltration, dynamics (rat), 833
Glucoorticoids, vasopressin-regulated urea transporter downregulation, inner medullary collecting ducts (rat), 517
Glucose, high
enhanced extracellular matrix production in mesangial cells (rat), 406
nitric oxide production inhibition (rat), 1276
GLUT2 gene, overexpression in renal proximal tubules, diabetic Zucker rats, 943
Glycation end products, advanced, osteoclast-induced bone resorption en-
hancement (rodent), 260
Glycemic control, diabetic nephropathy, 487
Glycopeptide, IgA1 hinge, IgA nephropathy, 915
Glycoprotein, platelet membrane, hemodialysis, 799
Glycosaminoglycans, tubular epithelium distribution, renal (rat), 586
Goodpasture syndrome, Wegener’s granulomatosis and anti-GBM disease overlap, 1795
Goodpasture’s disease, B cell epitope mapping in, 1698
Graft rejection, kidney transplant, late prednisone withdrawal, 294
Graft survival, cadaveric renal transplantation, cyclosporine-based regimens, 638
Granulomatosis, Wegener’s, anti-GBM disease with, 1795
Growth
neonatal kidney, bradykinin B2 receptors in (rat), 920
renal, angiotensin type 1 receptor related to, 193
Growth factor
insulin-like
multicystic renal dysplasia, 85
renal accumulation (mice), 436
platelet-derived, glomerular expression, 817
transforming: see Transforming growth factor
Growth hormone, pituitary cell secretion, uremia depression (rat), 742

H+-ATPase
intercalated cell, preservation, 1109
vacular, adaptational changes in remnant kidney (rat), 868
Han:SPRD rat, polycystic kidney disease, bithionol sulfonoxime aggravation, 1283
HDL: see High-density lipoprotein
Heart
left ventricular hypertrophy, 1292
chronic hemodialysis, 1764
risk profile, chronic hemodialysis patients, 475
Heart failure, renal nerve activity characteristics, reflex influences on (rat), 1232
Hematocrit, hemodialysis patients, low-dose subcutaneous erythropoietin in, 288
Hematuria, renal papillary necrosis, sickle cell trait, 1034
Hemodiafiltration, kinetics, clinical characterization, 494
Hemodialysis: see also Dialysis
acidosi
calcium sensitivity of parathyroid glands, 627
coma after, 853
whole-body protein degradation, 632
anaemia in, outcome prediction, 1921
blood volume changes, ultrafiltration-induced, 957
calcitriol removal, lack of, 1587
cerebrovascular accident risk, 1342
chronic cardiac risk profile, 475
left ventricular hypertrophy and plasma renin activity in, 1764
coronary artery disease prediction, 1889
debut-stage renal disease, 487
erythropoietin, low-dose subcutaneous, 288
graft, thrombolysis of, pulmonary embolism after, 1458
hepatitis B surface antigen-negative patients, hepatitis B virus DNA in serum and bone cells of, 1443
lipopolysaccharide-binding protein and bactericidal/permeability-increasing factor during, membranes, 463
PDGF and MCF-1 plasma concentrations, erythropoietin affecting, 1147
platelet membrane glycoproteins, 799
prescription, impaired delivery, 1315
serum antioxidant activity improvement, electron spin resonance showing, 1157
Hemodynamics
diabetic nephropathy, 487
glomerular, acyclovir and ganciclovir nephrotoxicity (rat), 361
hemofiltration, extracorporeal blood temperature, 949
renal allograft, Doppler sonography, 813
Hemofiltration, hemodynamic response during, extracorporeal blood temperature, 949
Hemorrhage, interstitial, renal allograft rejection with, 1930
Heparin, tubular epithelial distribution, renal (rat), 586
Heparin, polyaromatic anionic compound mimicking, receptor binding, 1688
Hepatitis B virus DNA in serum and bone cells, hemodialysis patients, 1443
Hepatocyte
aluminum uptake, p-cresol enhancement (murine), 935
impaired Na⁺⁻H⁺ exchanger activity, chronic renal failure (rat), 929
Herpesvirus, Kaposi’s sarcoma, post-transplant, 130
Heymann nephritis
passive, complement C4 synthesis in renal epithelium (rat), 214
plasminogen system changes, transformed proximal tubular epithelial cells in study of, 184
High-density lipoprotein
mesangial cell mitogenesis, tyrosine kinase-dependent receptor mechanism, 1247
phenotype of, coronary artery disease prediction, 1889
Histology, homologous albumin absorption, proximal tubule cell (rat), 323
HIV: see Human immunodeficiency virus
Homeostasis, potassium, 1179
Hormone
growth hormone releasing, pituitary cell secretion in response (rat), 742
renal function controlled by, 543
sex, nitric oxide synthase (rat), 1240
vasoactive, erythropoietin-induced hypertension not mediated by (rat), 901
Human immunodeficiency virus
kidney, 138
nephropathy associated with angiotensin-converting enzyme inhibition, 1140
electron microscopy, 70
Humorally mediated injury, Th2 responses induce, anti-glomerular basement membrane glomerulonephritis (murine), 1101
Hungry bone syndrome, prolonged, hyperparathyroidism with, 1626
Hyaluronan, peritoneal fluid absorption decrease, peritoneal dialysis, 1915
Hybridization, in situ, IL-4 in glomerulonephritis (human), 730
11β-Hydroxysteroid dehydrogenase type 2, IMCD, inhibition by low pH and acute acid loading, 530
Hypercalcaemia, pulse vitamin D3 therapy, CAPD patients treated with low calcium dialysate, 1579
Hyperfiltration, glomerular
sympathetic nervous system activation, 893
d-α-tocopherol prevention (rat), 426
Hyperglycaemia
mesangial cell hyperresponse, diabetic glomerular disease pathogenesis (rat), 406
renal hypertrophy, insulin-like growth factor I accumulation (mice), 436
Hyperhomocysteinemia, folate-induced reduction, uremia, 1899
Hyperkalaemia, distal renal tubular acidosis, intercalated cell H⁺-ATPase in, 1109
Hyperparathyroidism
hemodialysis, acidosis correction, 627
secondary, renal failure, 271, 993
severe, prolonged hungry bone syndrome with, 1626
Hyperperfusion, renal, sodium restriction exacerbation (human), 749
Hypertension
angiotensin II-induced, AT1 receptor blockade renal responses (rat), 535
chronic renal damage, angiotensin-converting enzyme inhibition to prevent (rat), 249
diabetic nephropathy, 487
erythropoietin-induced, mediation of (rat), 901
essential, sympathetic nervous system activation, 893
ET₄ receptor blockade prevention, exogenous endothelin-1 associated (rat), 1054
nephrosclerosis, glomerular filtration rate estimation, 279
Hypertrophy
glomerular, reversible, 1668
left ventricular
autosomal dominant polycystic kidney disease, 1292
chronic hemodialysis, 1764
renal compensatory, posttransplant, 368
insulin-like growth factor I accumulation (mice), 436
Hypoalbuminaemia, estrogen replacement, atherosclerotic risk enhancement, 1870
Hypokalaemia, 1179
cystic fibrosis presenting with, previously healthy adolescent, 352
Hyponatraemia
positive water balance absence, rat, 524
practical focus on therapy, 1599
Hypoparathyroidism, vitamin D receptor gene polymorphism with, chronic renal failure, 1546
Hypothesis
countercurrent, urinary concentrating mechanism, 153
intact nephron, Bright’s disease, 1470
Hypovolaemia
central, parathyroid hormone plasma concentration, 1574
treatment, 1599
ICAM-1: see Intercellular adhesion molecule-1
IgA: see Immunoglobulin A
Ileal pouch, absorption capacity, calcium malabsorption, 1553
IMCD: see Collecting duct, inner medullary
Immaturity, aquaporin-2 in, rat, 1502
Immune complex
glomerulonephritis, neutrophil and platelet infiltration in, P-selectin in, 1838
mesangial deposits, complement component C3 production enhancement, 1257
Immune globulin therapy, intravenous, renal insufficiency after, 1788
Immune injury, glomerular response, Cry modulation, 223
Immune complex, collagen derivation, endogenous type IV, 376
Immunoglobulin A nephropathy
clinical perspective, 1324
complement C3 gene expression, renal cortical, 415
fish oil therapy for, 1739
IgA1-IgA1 interaction, 915
interleukin-6 release from mesangial cell, serum lectin stimulation, 208
outcome prediction, multivariate analysis, 199
platelet-derived growth factor and PDGF receptor mRNA glomerular expression, 817
Immune globulin G, linear deposits, 1795
Immunohistochemical localization, interleukin-8 and TGF-β, streptococcal glomerulonephritis, 234
Immunological complication, lupus nephritis, diffuse proliferative, 1205
Immunosuppression, posttransplant, Kaposi’s sarcoma, 130
Induction therapy, antilymphocyte, renal allograft survival, 1771
Infection
cytomegalovirus
glomerular injury caused by, 1801
renal transplantation, 118, 1448
GB virus C, pretransplantation, 1164
human immunodeficiency virus, kidney, 138
Infiltration, lymphomatous, kidney, 1348
Inhibition
angiotensin-converting enzyme
chronic renal damage treated by (rat), 249
HIV-associated nephropathy, 1140
antisense, type IV collagen, 61
11β-hydroxysteroid dehydrogenase type 2, IMCD, 530
nitric oxide, endogenous, 1437
nitric oxide synthase
angiotensin II, 551
renal epithelial cells, 558
nitric oxide synthesis
renal effects, 543
vasoconstrictor response (rat), 887
synthetic, type IV collagenase (rat), 395
Inhibitor, cell cycle, overexpression, 51
Intact nephron hypothesis, Bright’s disease, chronic, 1470
β1 Integrin
mesangial cell expression, glomerulonephritis (human), 1679
tubular cell adhesion mediated by, axonie injury before (murine), 175
Intensive care, mortality prediction, acute renal failure treated with dialysis, 111
Intercalated cell, H+-ATPase preservation, lupus nephritis and tubular acidosis, 1109
Intercellular adhesion molecule-1
mesangial cell expression, murine, 596
neutrophil binding dependent on, cortical interstitium cells (human), 604
Interferon alfa therapy, posttransplant lymphoproliferative disorder, remission of, 1483
Interleukins
IL-2 receptor, proximal tubular epithelial cell expression, 1510
IL-4, glomerulonephritis (human), 730
IL-6, release from mesangial cell, serum lectin stimulation, 208
IL-8, stromalcoval glomerulonephritis, immunohistochemical localization, 234
International Study of Kidney Disease in Childhood
idiopathic nephrotic syndrome, treatment, 824
minimal change nephrotic syndrome, prognostic significance of early course, 769
Interstitium, cortical, myofibroblast-resembling cells (human), 604
Isoproterenol, angiotensinogen gene expression stimulation (opossum), 1072
Kaposi’s sarcoma, posttransplant, 130
Kidney: see also Renal
aquaporin-1 water channel expression, human, 1
artificial, dialyzer with a great area, 1959
aspiration biopsy, 1778
growth of, neonatal (rat), 920
human immunodeficiency virus infection, 138
lymphomatous infiltration, renal failure due to, 1348
mass reduction, hypertension associated with (rat), 1054
osteopontin in, ultrastructural localization, 1043
perfused, isolated (rat), 1391
remnant: see Remnant kidney
ROMK channels in, localization of (rat), 1823
transplantation: see Transplantation, kidney; Allograft water channel expression, reduced, 15
Kidney cell, opossum, angiotensinogen gene expression stimulation, 1072
Kidney Council, American Heart Association, editorial, 1624
Kidney disease
glomerulocystic: see Glomerulocystic kidney disease
progressive, mitochondrial tRNA<sup>Leu(UUR)</sup> gene mutation, 118
Kidney stone, risk, family history, 1568
Kinase
cyclin-dependent, glomerular expression, 368
signaling systems mediated by, 580
Kinetics, hemodiafiltration, clinical characterization, 494
Kinin blockade, neonatal kidney growth, rat, 920
Knee, β2-microglobulin amyloid deposits, tendon sheets, 509
L-754,142, renal protection by, aortic cross-clamping (dog), 1061
Lectin, serum, immunoglobulin A nephropathy, interleukin-6 release stimulation, 208
Leptin, serum immunoreactive, body fat content, chronic renal failure, 1423
Liddle’s syndrome, epithelial sodium channel, 980
Limitation, blood flow, peritoneal-blood solute transport, 471
Lipid emulsion, solubilization with, amphotericin B nephrotoxicity attenuation (rat), 1415
Lipopolysaccharide, osteopontin induction, ultrastructural localization in the kidney, 1043
Lipopolysaccharide-binding protein, hemodialysis, membranes, 463
Lipoprotein glomerulopathy
apolipoprotein E’s role, editorial, 840
apolipoprotein E Sendai with, human, 820
Liver disease, posttransplantation, pretransplantation GB virus C infection affecting, 1164
Localisation
immunohistochemical, interleukin-8 and TGF-β, streptococcal glomerulonephritis, 234
ROMK channels, kidney (rat), 1823
ultrastructural, osteopontin in the kidney, 1043
Luminal membrane, macula densa cell, 1831
Lupus erythematosus
autoimmunity, monocyte chemoattractant protein-1 renal expression (murine), 720
retropertoneal fibrosis with, 684
systemic, renal manifestations, 1188
Lupus nephritis
diffuse proliferative, propylthiouracil-induced, 1205
intercalated cell H+-ATPase in, preservation, 1109
membranous, electron microscopy, 70
mesangial, nephrotic syndrome associated with, 1199
Lymphocyte: see also B lymphocyte
anti-lymphocyte induction therapy, renal allograft survival, 1771
Lymphoma, renal failure due to, acute, 1348
Lymphoproliferative disorder, posttransplant, interferon alfa therapy, 1483
Macrophage
infiltration by, nitroarginine methyl ester treatment reducing (rat), 1712
proslecroric response promoted by, mesangial cells (rat), 1525
Macula densa cell, luminal membrane, 1831
Madin-Darby canine kidney cells, aquaporin-2 transfection, transcellular osmotic water transport reconstitution, 1493
Magnesium, adenylate cyclase activity related to, nephron isolated segments (rabbit), 1608
Malignancy, renal, tumor-associated glomerulonephritis, 848
Managed care, capitiation, future of nephrology, 1618
Mannitol, renal failure induced by, acute, 1028
Manpower, nephrology, editorial, 843
Mapping, B cell epitopes, Goodpasture’s disease, 1698
Mass reduction, renal, hypertension associated with (rat), 1054
Matrix deposition, mesangial cell, glomerulonephritis, 1679
Matrix metalloproteinase inhibitor, mesangial cell and, collagenase and cell proliferation inhibition (rat), 395
Matrix protein, gene expression and synthesis, platelet-activating factor stimulation, 1266
MCP: see Monocyte chemoattractant protein
Medulla, inner, nonurea versus total osmolality, 881
Membrane
apical, proximal tubule, 1213
hemodialysis, 463
Membrane protein, aspartate content, 95
Mesangial cell
activated, β₁-integrin expression, 1679
cell cycle regulation, 51
clusterin mRNA in, thrombin increasing (rat), 906
complement component C3 production, antigen-antibody complexes enhance, 1257
complement-mediated injury protection, Cry overexpression (rat), 223
dual-specificity protein-tyrosine phosphatases, differential regulation, 40 enhanced extracellular matrix production, genetic predisposition (rat), 406
glomerular antiproliferative activity, 1688
purified human, 1877
IL-6 release from, serum lectin stimulation, 208
lipopolysaccharide-stimulated, nitric oxide production, 1240
matrix metalloproteinase inhibitor and, collagenase and cell inhibition (rat), 395
matrix protein gene expression and synthesis, platelet-activating factor stimulation, 1266
mitogenesis, HDL causing, 1247
nitric oxide production, high glucose inhibits (rat), 1276
prosclerotic response in, macrophage promotion (rat), 1525
prostaglandin endoperoxide synthase mRNA expression and protein synthesis, endothelin induction (rabbit), 1080
RANTES and ICAM-1 expression, regulation of (murine), 596
Messenger ribonucleic acid
clusterin, thrombin increasing (rat), 906
IL-4, in situ hybridization study, 730
PDGF receptor, glomerular expression, 817
Meta-analysis
fish oil therapy for IgA nephropathy, 1739
renal allograft survival, anti-lymphocyte induction therapy, 1771
Metabolism
alkalosis, 1462
fibroblast collagen, diabetic nephropathy, 1133
folate-induced reduction of hyperhomocysteinemia, uremia, 1899
protein, varying amino acid levels (rat), 1399
redox, polycystic kidney disease aggravation, 1283
skeletal, bone density and, 1553
Microangiopathy, thrombotic, ticlopidine therapy with, 689
Microenzymatic technique, adenylyl cyclase activity measurement, nephrin isolated segments (rabbit), 1608
β2-Microglobulin, amyloidosis, chronic dialysis patients, 509
Microperfusion, single proximal tubule, homologous albumin absorption (rat), 323
Micropuncture, urinary concentrating mechanism studied by, countercurrent hypothesis, 153
Microvascular action, renal, thromboxane mimetic U44069, 25
Mimetic, heparin, antiproliferative activity, 1688
Mineralocorticoid excess, volume expansion with, metabolic alkalosis with, 1462
Minimal change disease, idiopathic nephrotic syndrome, 824
Mitochondrium, tRNALeu(UUR) gene mutation, progressive kidney disease, 1118
Mitogenesis, mesangial cell
glomerular, verocytotoxin inhibits, 1877
HDL causing, 1247
Model, computer-based, renal replacement therapy, 804
Monitoring, cytomegalovirus infection, renal transplantation, 1448
Monocyte, circulating, cytokine generation by, 1745
Monocyte chemoattractant protein cell, tubular, nitric oxide synthase inhibition, 551
Monocyte chemoattractant protein-1 antibody, anti-glomerular basement membrane nephritis suppression, WKY rat, 1174
proximal tubule cells, urinary protein induction, 1537
renal expression, lupus autoimmune mice, 720
Mononuclear cell, peripheral blood, viral DNA in, 1443
Morbidity
cytomegalovirus-associated, renal transplant patients, 118
dialysis-related, monocyte cytokine secretion, 1745
Mortality prediction, intensive care patients, acute renal failure treated with dialysis, 111
mRNA: see Messenger ribonucleic acid
Multivariate analysis, outcome prediction, immunoglobulin A nephropathy, 199
Mutation
AQP2 gene, nephrogenic diabetes insipidus, water channel misrouting, 242
mitochondrial (tRNALeu(UUR) gene, progressive kidney disease, 1118
NKCC2, Costa Rican Barter’s syndrome, 1706
vasopressin V2 receptor and aquaporin-2 genes, congenital nephrogenic diabetes insipidus, 1855
Mycoplomate, cost-effectiveness, posttransplantation, 1592
Myofibroblast, cortical interstitium cells resembling, human, 604
Na⁺-H⁺ exchanger activity, hepatocyte, chronic renal failure (rat), 929
Necrosis, papillary, renal, 1034
Neobladder, orthotopic ileal, bone density and, 1553
Neural, cyclosporine area under the curve prediction after, three-point sampling strategy, 647
Nephrectomy, subtotal, secreted protein rich in cysteine after (rat), 1374
Nephritis
acute, IL-8 and TGF-β immunohistochemical localization, 234
anti-glomerular basement membrane, anti-monocyte chemoattractant protein-1 antibody suppression (rat), 1174
Heymann: see Heymann nephritis
immune-complex, renal endothelin-1 expression and synthesis (rat), 756
lupus: see Lupus nephritis
nephrototoxic, nitric oxide’s role in, 1712
Nephrogenesis, epithelial galectin-3, 1647
Nephrology
curriculum core, 1019
editorial, 1016
future workforce estimation and training requirements, S1
managed care and capitation affecting, 1618
pediatric, future workforce need estimation, S5
Nephrology Manpower Study, editorial, 843
Nephron
African Americans with, proteinuria in, 793
bone marrow transplant, 166
diabetic, 487
danaparoid sodium lowers proteinuria in, 456
HIV-associated, 138
angiotensin-converting enzyme inhibition, 1140
immunoglobulin A: see Immunoglobulin A nephropathy
insulin-dependent diabetic patients with, skin collagen synthesis, 1133
membranous, electron microscopy, 70
obstructive, retroperitoneal fibrosis causing, 684
radiocorlustransisted, adenosine antagonist prevention (rat), 1125
Nephrosclerosis, hypertensive, glomerular filtration rate estimation, 279
Nephrosis
chronic puromycin aminoacrolein, osteopontin in (rat), 1383
osmotic, mannitol-induced, 1028
protein metabolism in, varying amino acid levels (rat), 1399
renal nerve activity characteristics, reflex influences on (rat), 1232
Nephrotic syndrome
idiopathic, treatment, 824
membranous glomerulonephritis causing, 664
mesangial lupus nephritis with, 1199
minimal change, prognostic significance of early course, 769
puromycin aminonucleoside-induced, reduced renal medullary water channel expression, 15

Nephrotoxicity
acetylcysteine treatment, 1640

Nervous system, sympathetic, activation in early essential hypertension, 893

Neutrophil
corticosteroid binding, ICAM-1 dependent manner (human), 604
infarction, immune complex glomerulonephritis, P-selectin in, 1838

Nitric oxide
chronic deficiency, radiocontrast-induced nephropathy prevention (rat), 1125
high glucose inhibition, rat mesangial cells, 1276
inhibition, renal effects, 543
nephrotoxic nephritis, rat, 1712
synthesis of, acetate tolerance mediated by, 1431

Nitric oxide inhibitor, endogenous, dialysis patients, 1437

Nitric oxide synthase
inducible
angiotensin II inhibition, 551
nephrotoxic nephritis (rat), 1712
inhibition, renal epithelial cells, 558
renal, sex hormones and (rat), 1240

Nitric oxide synthesis, inhibition, vasoconstrictor response (rat), 887
NKCC2 mutation, Costa Rican Bartter’s syndrome, founder effect, 1706
Nutrition, total parenteral, protein metabolism in (rat), 1399
Nutritional status, hemodialysis, metabolic acidosis correction, 632

Obstruction, urinary tract, fetal, 653

Osmolarity, nonurea versus total, inner medulla, 881
Osmotic demyelination syndrome, risk factors, 1599
Osmotic shock, adenyate cyclase activity, nephron isolated segments (rabbit), 1068

Osteoblast, bone resorption induced by, advanced glycation end product enhancement (rodent), 260
Osteomyelitis, staphylococcal, diffuse proliferative glomerulonephritis and acute renal failure with, 1633

Osteopenia
nephrosis, chronic puromycin aminonucleoside (rat), 1383
ultrastructural localization, kidney, 1043

Outcome, renal transplantation, pretransplantation GB virus C infection affecting, 1164

Outcome prediction
anaemia in haemodialysis patient, 1921
nephropathy, immunoglobulin A, 199

Overexpression
Cry, mesangial cell protection from complement-mediated injury (rat), 223
GLUT2 gene, renal proximal tubules of diabetic Zucker rats, 943
Oxidant stress, cardiac risk profile, chronic haemodialysis patients, 475
Oxygen species, reactive, antioxidant defense and, 1722

p16ink4a and p21cip1, overexpression, mesangial cell proliferation increase, 51

PAC1, mesangial cell, differential regulation, 40

PAF: see Platelet-activating factor

PAN: see Puromycin aminonucleoside

Parathyroid glands, calcium sensitivity, acidosis correction to increase, 627
Parathyroid hormone
decreasing serum level, CAPD patients, 1579

mild renal failure (rat), 271
plasma concentration, volume depletion and central hypovolemia influencing, 1574
Parathyroidectomy, hyperparathyroidism secondary to renal failure, 993
Pathogenesis
nephropathy, HIV-associated, 138
tubulointerstitial lesion, mesangial proliferative glomerulonephritis (rat), 1363

Pathophysiology, atrial natriuretic peptide, renal patients, 445
PGDF: see Platelet-derived growth factor

Peptide
atrial natriuretic, pathophysiological role and diuretic efficacy, renal patients, 445
endothelin, 32

Perfusion, tubule, rabbit, 675

Peritoneal dialysis
cerebrovascular accident risk, 1342
chronic, total body water and body composition, 1906
continuous, survival probability, United States compared with Canada, 965
continuous ambulatory
pulse vitamin D3 therapy, 1579
salt intake, 1311
peri toneal fluid absorption, hyaluronan decreases, 1915
visceral blood flow limitation, 1946
Peritoneal fluid, absorption decrease, hyaluronan, 1915
Peritoneum
transport, blood flow limitation, 471
visceral, solute transport across, 1946
Permeability, water, vasopressin modification (touad), 1005
pH, low, IMDC 11β-hydroxysteroid dehydrogenase type 2 inhibition by, 530
Phosphatase, protein-tyrosine, dual-specificity, 40
Pituitary cell, growth hormone secretion, uremia depression (rat), 742

Plasma
endothelin, erythropoietin-induced hypertension not mediated by (rat), 901
PGDF and MCP-1 in, hemodialysis, 1147

Plasma exchange, thrombotic microangiopathy treated with, 689

Plasma renin activity, left ventricular hypertrophy related to, chronic hemodialysis, 1764

Plasminogen system, proximal tubular epithelial cell, transforming growth factor effects (rat), 184
Platelet infiltration, immune complex glomerulonephritis, P-selectin in, 1838
Platelet membrane, glycoproteins, hemodialysis, 799
Platelet-activating factor
matrix protein stimulation, mesangial cells, 1266
proteinuria mediated by, angiotensin II induction (rat), 1391
Platelet-derived growth factor, glomerular expression, IgA nephropathy, 817

Podocyte
culture, induction of differentiation (rat and human), 697
glomerular epithelial cell like, renin-angiotensin system component expression (murine), 706

Polycystic kidney disease
anion secretion, organic (rat), 1222
autosomal dominant, 77
arterial complications, 616
derend-stage renal disease risk, 1560
intracranial arterial dolichoectasia, 1298
left ventricular hypertrophy, 1292
ultrasonography in children, 105
buthionine sulfoximine aggravation, Han:SPRD rats, 1283

Polycystin, vascular expression, 616

Polymerase chain reaction, cytomegalovirus treatment based on, renal transplant patients, 118

Polyomorphism
insertion/deletion, angiotensin-converting enzyme, 1319
vitamin D receptor gene, hypoparathyroidism associated with, 1546
Polyuria, hypokalemia, 1179

Potassium
homeostasis, 1179
luminal, tubuloglomerular feedback, 1831
Potassium channel, secretory, apically located (rat), 1823
Prediction, cyclosporine area under the curve, three-point sampling strategy, 647
Prediction models, intensive care patients, acute renal failure, 111
Prednisone
late withdrawal, cyclosporine-treated kidney transplant patients, 294
lupus glomerulonephritis treatment, 1188
Prescription, hemodialysis, impaired delivery, 1315
Presidential address, 972
Procollagen α1(IV), antisense cDNA for, transfection, 61
Prognosis, minimal change nephrotic syndrome, early course, 769
Proliferation
cell, matrix metalloprotease inhibition (rat), 395
glomerular endothelial cell, transfection of antisense cDNA for procollagen α1(IV) affecting, 61
mesangial, diffuse, 824
mesangial cell, cell cycle inhibitor overexpression regulation, 51
Propylthiouracil, lupus nephritis induced by, diffuse proliferative, 1205
Prosclerotic response, macrophage promotion, mesangial cells (rat), 1525
Prostaglandin synthesis inhibition, renal effects, 543
Prostaglandin endoperoxide synthase, mRNA expression, endothelin induction (rabbit), 1080
Protein
acidic, subtotal nephrectomy preceding (rat), 1374
aquaporin-2 water channel, urinary excretion (human and rat), 1387
cAMP-responsive element binding, angiotensinogen gene expression stimulation (opossum), 1072
damaged, repair, 95
degradation, whole-body, 632
intake, renal disease, 777
lipopolysaccharide-binding, hemodialysis, 463
matrix: see Matrix protein
metabolism, varying amino acid levels (rat), 1399
monocyte chemoattractant, proximal tubule cells, 1537
restriction, moderate renal disease progression, erratum, 493
synthesis, verocytotoxin inhibits, 1877
Protein load, acute oral, renal acidification (human), 784
Protein tyrosine phosphorylation, calcium-regulated, 1080
Protein-tyrosine phosphatases, dual-specificity, differential regulation in mesangial cell, 40
Proteinuria
angiotensin II induced, platelet-activating factor mediates (rat), 1391
angiotensin-converting enzyme inhibition, 1140
calcium channel blockade versus converting enzyme inhibition, African Americans with NIDDM and nephropathy, 793
danaparoid sodium lowers, diabetic nephropathy, 456
glomerulomegaly with, idiopathic pulmonary hypertension, 1966
idiopathic nephrotic syndrome, pathophysiology, 824
mesangial proliferative glomerulonephritis with, rat model, 1363
monocyte chemoattractant protein-1 induction, proximal tubule cells, 1537
monocyte-macrophage infiltration causing, rat, 1174
Proteoglycans, tubular epithelium distribution, renal (rat), 586
Proximal tubular cell
monocyte chemoattractant protein-1 in, urinary protein induction, 1537
nitric oxide synthase inhibition, angiotensin II, 551
Proximal tubule
angiotensin II receptor expression, regulation, 306
apical membrane, conjugate export pump encoded by mnp2 gene, 1213
cisplatin nephrotoxicity, clusterin temporal induction (rat), 302
electrolyte content, rabbit, 675
homologous albumin absorption (rat), 323
renal, GLUT2 gene overexpression (rat), 943
P-selectin, neutrophil and platelet infiltration, immune complex glomerulonephritis, 1838
Pseudohypokalemia, 1179
Pulmonary hypertension, idiopathic, glomerulomegaly and proteinuria with, 1966
Pulse vitamin D3 therapy, hypercalcemia during, CAPD patients treated with low calcium dialysate, 1579
Puromycin aminonucleoside
glomerulopathy, reactive oxygen species and antioxidant defense in, 1722
nephrosis chronic (rat), 1383
reduced renal medullary water channel expression, 15
Quinapril, renal endothelin-1 expression and synthesis decreased by, immune-complex nephritis (rat), 756
Radiation therapy, bone marrow transplant, nephropathy after, 166
Radiocontrast, nephropathy induced by, adenosine antagonist prevention (rat), 1125
RANTES (regulated upon activation, normal T cell expressed and secreted), mesangial cell expression, murine, 596
Receptor
angiotensin II
neprhon (rat), 1658
proximal tubule, 306
angiotensin type 1, regulation and gene expression, renal growth related to, 193
bradykinin B2, neonatal kidney growth (rat), 920
endothelin, subtypes, 32
Reflex influences, renal nerve activity, nephrosis and heart failure (rat), 1232
Rejection
renal allograft, acute, 1930
transplant, renal, 1517
Remission, posttransplant lymphoproliferative disorder, interferon alfa therapy, 1483
Remnant kidney
angiotensin II and TGF-β1 interaction in (rat), 1732
vacular H+-ATPase in, adaptational changes (rat), 868
Remodeling, mesangial, pathological, 1679
Renal cell, epithelial sodium channel α subunit, synthesis rate, 1813
Renal cystic disease, hypokalemia, 1179
Renal disease
end-stage
aluminum accumulation in the liver, 935
autosomal dominant polycystic kidney disease causing, 1560
cerebrovascular accident risk, 1342
family history of, 1942
managed care and capitation affecting treatment, 1618
moderate, dietary protein restriction, erratum, 493
protein intake, 777
Renal failure
acute
dialysis treatment, mortality prediction, 111
extracorporeal therapy, 804
human immunodeficiency virus infection, 138
lymphomatous infiltration of kidneys, 1348
mannitol-induced, 1028
osteoarthritis with, 1633
chronic
growth hormone secretion (rat), 742
impaired hepatocyte Na+-H+ exchanger activity (rat), 929
leptin concentration related to body fat content, 1423
metabolic acidosis correction, 632
renal acidification (human), 784
vitamin D receptor gene polymorphism and hypoparathyroidism in, 1546
incipient, secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements (rat), 271
secondary hyperparathyroidism, treatment, 993
tumor-associated glomerulonephritis, unusual, 848
Renal injury, cisplatin, clusterin temporal induction (rat), 302
Renal insufficiency
immune globulin therapy, intravenous, 1788
metabolic alkalosis with, 1462
Renal mass, reduced, endothelin in, 1054
Renal nerve
activity characteristics, reflex influences on (rat), 1232
vasoconstrictor response not mediated by, nitric oxide synthesis inhibition (rat), 887
Renal replacement therapy, acute renal failure, computer-based model, 804
Renal responses
AT1 receptor blockade, hypertensive rats, 535
nitric oxide and prostaglandin synthesis inhibition, angiotensin II in, 543
Renin, cardiac hypertrophy, chronic hemodialysis, 1764
Renin-angiotensin system
blockade, secreted protein rich in cysteine after (rat), 1374
glomerular epithelial cell expression, culture, (murine), 706
proximal tubule, 306
Resorption, bone, osteoclast-induced, 260
Respiratory burst, apoptosis modulation, 1091
Ribonuclease protection assay, endothelin-converting enzyme expression, glomerular endothelial cells, 580
Risk factors, withdrawal from dialysis before death, 1755
Risk profile, cardiac, chronic hemodialysis patients, 475
ROMK channel, kidney localization, rat, 1823
Salt intake, continuous ambulatory peritoneal dialysis, too restrictive, 1311
Sampling strategy, three-point, cyclosporine area under the curve prediction, 647
Sandimmune, cyclosporine area under the curve prediction after, three-point sampling strategy, 647
Sclerosis, glomerular, focal, 249
Secreted protein acid rich in cysteine, expression of, subtotal nephrectomy preceding (rat), 1374
Secretion
cytokine, monocyte, 1745
growth hormone, chronic renal failure (rat), 742
organic anion, polycystic kidney disease (rat), 1222
Serum
antioxidant activity, hemodialysis increasing, 1157
circulating lectin, immunoglobulin A nephropathy, interleukin-6 release stimulation, 208
uremic, dimethylarginine levels, 1437
Sex hormones, nitric oxide synthases, renal (rat), 1240
Shell vial assay, cytomegalovirus infection, renal transplantation, 1448
Sickle cell trait, renal papillary necrosis, 1034
Signal transduction, microvascular resistance regulation, 569
Signaling system, kinase-mediated, endothelin-converting enzyme expression, 580
Skeletal metabolism, bone density, orthotopic ileal neobladder, 1553
Skin, cultured fibroblasts, insulin-dependent diabetic patients with nephropathy, 1133
Smooth muscle, arterial, polycystin expression, 616
Smooth muscle cell, renal microvascular, agonist-induced calcium regulation (rat), 569
Sodium
danaparoid, proteinuria lowered by, diabetic nephropathy, 456
reabsorption, kidney (rat), 524
rerenal handling, atrial natriuretic peptide’s role, 445
Sodium channel, epithelial
α subunit, 1813
β subunit, amiloride-sensitive, 126
blood pressure control, 980
Sodium depletion, angiotensin type 1 receptor upregulation, renal growth related to, 193
Sodium intake, continuous ambulatory peritoneal dialysis, too restrictive, 1311
Sodium restriction, early diabetes mellitus, renal responses (human), 749
Solute
clearance pattern, hemodiafiltration, 494
peritoneal-blood transport, blood flow limitation, 471
transport, blood flow limitations of, 1946
Sonography, Doppler, graft monitoring, 813
SPARC: see Secreted protein acidic and rich in cysteine
Stabilizing agent, immune globulin therapy, intravenous, 1788
Staphylococcus, osteomyelitis, diffuse proliferative glomerulonephritis and acute renal failure with, 1633
Stenosis, fistula, hemodialysis, 1147
Steroids, cyclosporine combined with, cadaveric renal transplantation, 638
Stone, kidney, family history, 1568
Stress, oxidant, cardiac risk profile, 475
Stroke: see also Cerebrovascular accident
intracranial arterial dolichoectasia, polycystic kidney disease, 1298
Subtype, endothelin receptor, endothelin-1 systemic and renal responses, 32
Superoxide, neutrophil release
ANCA-antigen crosslinking stimulation (human), 386
apoptosis, 1091
Survival
continuous peritoneal dialysis, United States compared with Canada, 965
renal allograft, anti-lymphocyte induction therapy, 1771
Synthesis
collagen, enhanced, 1133
complement C4, renal epithelium, passive Heymann nephritis (rat), 214
epithelial sodium channel α subunit, aldosterone’s effect on, 1813
matrix protein, platelet-activating factor stimulation, 1266
nitric oxide, acetate intolerance mediated by, 1431
prostaglandin, renal effects of inhibition, 543
Temperature, blood, extracorporeal, 949, 957
Th2 responses, humoral mediated injury induced by, anti-glomerular basement membrane glomerulonephritis (murine), 1101
Thrombin, clusterin mRNA increased by, glomerular epithelial and mesangial cells (rat), 906
Thrombocytopenic purpura, thrombotic, ticlopidine therapy with, 689
Thrombolysis, hemodialysis graft, pulmonary embolism after, 1458
Thrombosis, vascular, recurrent, 1477
Thromboxane, mimetic U44069, afferent arteriole preferential constriction, 25
Ticlopidine therapy, thrombotic thrombocytopenic purpura with, 689
Toad, isolated bladder, water movement through, 1005
d-α-Tocopherol, glomerular dysfunction prevention, diabetic rats, 426
Toxicity, renal, cisplatin-induced, 1640
Training
future requirement, S5
nephrology editorial, 846
estimation, S1
Transcriptional regulation, aquaporin-2 water channel gene, cAMP, 861
Transfection
antisense cDNA for procollagen α1(IV), glomerular endothelial cell proliferation, 61
aquaporin-2, transcellular osmotic water transport reconstitution (dog), 1493
Transfoming growth factor
plasminogen system effects, proximal tubular epithelial cells (rat), 184
TGF-β
streplococcal glomerulonephritis, immunohistochemical localization, 234
vitamin C or E effects (rat), 1405
TGF-β1, angiotensin II interaction with, 1732
Transplantation
bone marrow, nephropathy, 166
cadaveric
cyclosporine-based regimens, 638
primary, 1592
cytomegalovirus infection, monitoring and diagnosis, 1448
Kaposi’s sarcoma after, 130
kidney
cyclosporine-treated, late prednisone withdrawal, 294
cytomegalovirus-associated morbidity, intensive monitoring to control, 118
GB virus C infection, 1164
IgA nephropathy, 1324
intrarenal Doppler indices, 813
prolonged hungry bone syndrome in, 1626
recurrent vascular thrombosis, 1477
lymphoproliferative disorder after, interferon alfa therapy, 1483

Transport
PAH, perfused proximal tubule, 675
peritoneal-blood solute, blood flow limitation, 471
Transporter, urea, vasopressin-regulated (rat), 517
tRNA\text{Leu(UUR)} gene, mutation, progressive kidney disease, 1118

Tubular cell, renal, \beta1 integrin-mediated adhesion between, anoxic injury before (murine), 175

Tubular epithelial cell
Fas (CD95) expression and function, renal (human), 1517
proximal
IL-2 receptor expression, 1510
transforming growth factor effects on plasminogen system (rat), 184

Tubular epithelium, renal, glycosaminoglycan distribution (rat), 586

Tubular necrosis, cisplatin nephrotoxicity, clusterin temporal induction (rat), 302

Tubule
convoluted, proximal, 77
distal, osteopontin in, 1043
proximal: see Proximal tubule

Tubuloglomerular feedback, luminal potassium, potential role, 1831

Tubulointerstitial lesion, complement in pathogenesis, mesangial proliferative glomerulonephritis (rat), 1363

Tumor necrosis factor, TNF\text{a}, apoptosis mediated by, 1091

Tyrosine kinase, receptor mechanism dependent on, mesangial cell mitogenesis, 1247

U44069, thromboxane mimetic, afferent arteriole preferential constriction, 25
Ultrafiltration
blood volume changes induced by, hemodialysis, 957
glomerular, dynamics (rat), 833
hemodiafiltration, 494

Ultrasonography, autosomal dominant polycystic kidney disease, pediatric, 105

Ultrastructure, proximal tubule cell, 323
United States, continuous peritoneal dialysis survival, 965
Upregulation, angiotensin type 1 receptor, sodium depletion to induce, 193

Uptake, aluminum, hepatocyte (murine), 935
Urea, transporter, vasopressin-regulated (rat), 517

Urea kinetic modeling
dietary protein intake, 777
hemodialysis adequacy, 1315

Urea load, water deprivation, inner medulla osmolality, 881

Uremia
erthrocyte membrane protein, D-aspartate content decrease, 95
growth hormone secretion depressed by, pituitary cells (rat), 742
hyperhomocysteinemia in, folate-induced reduction, 1899
platelet dysfunction, hemodialysis, 799

Urinary concentrating mechanism, micropuncture study of, countercurrent hypothesis, 153

Urinary excretion, aquaporin-2 water channel protein, human and rat, 1357
 Urinary protein, monocyte chemoattractant protein-1 induction, proximal tubule cells, 1537

Urinary tract, fetal, obstruction, 653

Urine
concentrating ability
aquaporin-2 in (rat), 1502
familial hypohyhalamic diabetes insipidus (rat), 1333
flow rate, water deprivation, inner medulla osmolality, 881
Uropathy, obstructive, fetal, 653

Vacuole
apical, albumin uptake, 323

H\text{+}-ATPase, remnant kidney (rat), 868
Vascular expression, polycystin, 616
Vascular resistance, forearm, cold hemofiltration effects, 949
Vasculitic syndrome, pulmonary-renal and renal-dermal, 314
Vasculitis
immunosuppressive therapy, infectious cause, 1971
small-vessel, anti-neutrophil cytoplasmic autoantibodies, 314

Vasoconstriction, nitric oxide synthesis inhibition causing, renal nerve not mediating (rat), 887
Vasoconstrictor agonist, calcium regulation induced by, renal microvascular smooth muscle cells (rat), 569

Vasopressin
arginine, secretion, 1863
cellular actions, 1951
deficiency, familial hypothalamic diabetes insipidus (rat), 1333
erthropoietin-induced hypertension not mediated by (rat), 901
transcellular osmotic water transport regulation, aquaporin-2 transfection (dog), 1493
urea transporter regulated by, glucocorticoid downregulation (rat), 517
water movement modification, isolated toad bladder, 1005
Vasopressin V2 receptor, mutation in, congenital nephrogenic diabetes insipidus, 1855

Vasoregulation, renal, early diabetes mellitus (human), 749

Verocytotoxin, mitogenesis and protein synthesis inhibition, glomerular mesangial cell, 1877

Virus, hepatitis B, hemodialysis patients, 1443

Vitamin C or E, albuminuria, glomerular TGF\text{b}, and glomerular size affected by, diabetes (rat), 1405

Vitamin D
pulse therapy, hypercalcemia during, 1579
receptor binding to vitamin D response elements, incipient renal failure (rat), 271
receptor gene polymorphism, hypoparathyroidism associated with, 1546

E: see d\text{-Tocopherol}
Volume, dialysis, adequacy targets affected by, 1304
Volume contraction, metabolic alkalosis with, 1462
Volume depletion, parathyroid hormone plasma concentration, dialysis patients, 1574

Water balance, positive, hyponatremia in absence of (rat), 524

Water channel
aquaporin-1 expression
erratum, 358
kidney, human, 1
aquaporin-2, transcriptional gene regulation (murine), 861
aquaporin-2 protein, urinary excretion (human and rat), 1357
medullary expression, reduced, 15
misrouting, nephrogenic diabetes insipidus, 242

Water deprivation, urine flow rate during, inner medulla osmolality, 881

Water movement, vasopressin modification, isolated toad bladder, 1005

Wegener's granulomatosis, anti-GBM disease with, Goodpasture syndrome involving, 1795

Withdrawal
dialysis, risk factors, 1755
late prednisone, cyclosporine-treated kidney transplant patients, 294

Workforce, nephrologist estimation, editorial, 846
future, S1
pediatric, S5

Zucker rat, diabetic, GLUT2 gene overexpression in renal proximal tubules, 943

Zymography, quantitative and reverse, 395
NEPHROLOGY-PORTLAND OREGON

Northwest Permanente, P.C., a physician-managed, multispecialty group, has an excellent opportunity for a BC/BE Nephrologist in the Portland area. The Northwest Division has two nephrologists on staff providing quality care to nearly 420,000 members of Kaiser Permanente in Oregon and Washington. Ours is a collegial and stimulating practice and has a predictable schedule allowing time to pursue personal and family interests. In addition to a quality lifestyle inherent to the Pacific Northwest, we offer a competitive salary and benefit package which includes professional liability coverage, a comprehensive pension program, sabbatical leave and more. For additional information please forward a brief CV with cover letter to: N.P. Weiland, M.D., Regional Medical Director, NORTHWEST PERMANENTE, P.C., 500 NE Multnomah, Suite 100, Portland, OR 97232-2099. Phone 800-813-3763. EOE.

NEPHROLOGIST

Gundersen Lutheran is seeking a Board Certified/Board Eligible General Nephrologist. Gundersen Lutheran is a multi-specialty group practice with over 300 physicians. We are a modern, state of the art facility adjacent to a 402-bed hospital with Level II Trauma Center. In addition, the Gundersen system includes 36 regional community clinics based throughout western Wisconsin, eastern Minnesota and northeast Iowa.

La Crosse, Wisconsin nestled between towering bluffs is located where the Mississippi, La Crosse and Black Rivers merge. The area was untouched by the glaciers, leaving many hills and valleys as an outstanding scenic area. The metropolitan area of La Crosse, with its 100,000 people, offers exceptional year round opportunities for recreational activities.

Gundersen Clinic offers excellent working conditions and fringe benefits. Salaries are competitive. Interested candidates should send a letter of application and curriculum vitae to Frank Perez-Guerra, Manager, Recruitment, Retention and Resource Planning, Gundersen Lutheran, 1836 South Avenue, La Crosse, WI 54601; or call Frank Perez-Guerra at 1-800-362-9567.

Readers:

Williams & Wilkins classified advertising can now be found on the Internet - even before the ads appear for the first time in print! Look for the latest medical employment opportunities from Williams & Wilkins journals at:

http://www.wwilkins.com/classifieds

Advertising from the following journals can be found on-line:

American Journal of Gastroenterology
American Journal of Physical Medicine & Rehabilitation
American Journal of Sports Medicine
Anesthesia & Analgesia
Clinician Reviews
Clinical Nurse Specialist
Critical Care Medicine
Current Surgery
Diseases of the Colon & Rectum
Gastroenterology Nursing
Health Physics
The Hearing Journal
Journal of the American Geriatric Society
Journal of the American Society of Nephrology
Journal of Orthopaedic & Sports Physical Therapy
Journal of Trauma

Advertisers:

More people access the Internet every day. Don't overlook this opportunity to increase your classified advertisement's exposure at no additional cost. Call a W&W Classified Advertising representative right now for more information.

Jason Pointe (800) 528-5660
Michael Faulkner (800) 528-1843
James Weigand (800) 269-4339
Shouldn’t you be among the many physicians who rely on *Medicine*?

Analytical Reviews of Internal Medicine, Dermatology, Neurology, Pediatrics, Psychiatry, and Reviews in Molecular Medicine

Subscribe to *Medicine* and you’ll…

➤ Gain insight from leading scholars about the latest results in clinical investigation.

➤ Review in-depth major medical topics relevant to both hospital and office practice.

➤ Stay up-to-date through *Medicine’s* timely practice-oriented reports of significant clinical observations.

Money-Back Guarantee

If you are not completely satisfied with this journal, you may cancel at any time and receive a full refund or credit on all unmailed issues.

Here’s what our readers have to say:

“Excellent journal, fine balance and very outstanding scholarship.”

“First-rate journal, I highly recommend it for residents, fellows, students.”

“One of the best for ‘state-of-the-art’ yet practical reviews.”

Williams & Wilkins
A WAVERLY COMPANY
Visit our web site:
http://www.wwilkins.com

4 EASY WAYS TO ORDER

CALL 1-800-638-6423
Outside the U.S.: 410-528-8555
London: 171-643-4848
Hong Kong: 852-2810-2339
Tokyo: 03-5689-5400

FAX 410-528-8596

E-MAIL custserv@wwilkins.com

MAIL order form today to:
Williams & Wilkins
P.O. Box 23291
Baltimore, MD 21203-9990

Yes, start my subscription to *Medicine* today.

☐ Individual $98/year
☐ Institutional $195/year
☐ In-training* $59/year

(Add $30/year outside the U.S. & Canada, add GST and HST)

Subscribe for up to 3 years at the current rate!

☐ 3 years ☐ 2 years ☐ 1 year

PAYMENT OPTIONS: ☐ Bill me
☐ Check enclosed (payable to Williams & Wilkins)
☐ Am Ex ☐ MC ☐ VISA ☐ Discover

Card # Exp. date

Signature/P.O. #

Name

Address

City/State/Zip

Phone Fax

E-mail

MD subscribers add state sales tax. Orders outside the U.S. must be prepaid in U.S. dollars only. Rates valid through October 31, 1998. Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the U.S. may take up to 16 weeks. Airmail rates available upon request.

*Please specify institution & training status

MD 58664 Printed in USA
Yes, please start my subscription to JASN.

U.S.                          Outside the U.S.
☐ Individual $279.00/yr.         ☐ Individual $344.00/yr.
☐ Institutional $389.00/yr.      ☐ Institutional $454.00/yr.
☐ In-training* $112.00/yr.       ☐ In-training* $177.00/yr.

In Canada, add GST and HST.
Subscribe for up to 3 years at the current rate ☐ 3 yrs  ☐ 2 yrs  ☐ 1 yr

Payment Options: ☐ Check enclosed (payable to Williams & Wilkins)
☐ Bill me    ☐ Am Ex    ☐ MasterCard    ☐ VISA    ☐ Discover

Card #                      Exp. date
Signature/PO. #
Name
Address
City/State/Zip

MD subscribers add 5% state sales tax. Orders outside the U.S. must be prepaid in U.S. dollars only. Rates valid through October 31, 1998.

* Please specify institution and training status

ASN members receive the journal as a benefit of their membership.

Return this coupon to: Williams & Wilkins
P.O. Box 23291
Baltimore, MD 21203-9990

Internet address: custserv@wwillkins.com
http://www.wwillkins.com

ASN 58753

* Ranks first for impact among 37 journals in the urology and nephrology category (Science Citation Index, 1995)
Minding P's & Q's

A high priority at Williams & Wilkins.

People and Quality are the P's and Q's Williams & Wilkins cares about. We put the two together because we believe the people who are important to us—our valued, longstanding subscribers—deserve the best quality products and services we can provide.

INFORMATION FOR SUBSCRIBERS

[ ] CHANGE OF ADDRESS. Please notify us eight weeks in advance. Send us your mailing label or your account number, along with your new address, and the date the change of address is to take effect.

[ ] RENEWALS. To ensure uninterrupted service, please renew your subscription two months prior to the expiration date of your current subscription. Current rates are available for up to three years.

[ ] BACK COPIES. Would you like to order back copies of your journal? To place an order or to obtain single copy prices, please contact the Customer Service Department at the toll-free number shown below.

[ ] CLAIMS OR CANCELLATIONS. Claims for missing or damaged issues are honored for three months after the mailing date of the issue. If, for any reason, you are not satisfied with your subscription, you may cancel and receive a full refund on all unmailed issues.

[ ] MICROFORM/CD-ROM. Most titles are available on microfilm or microfiche the following year after publication. Several titles are available on CD-ROM. For more information, call Customer Service, using the toll-free number.

[ ] BOUND VOLUMES. Bound volumes are available direct from Williams & Wilkins. For prices and availability, contact the Subscription Department (at the address or toll-free number shown).

Satisfaction Guaranteed!
If, for any reason, you are not completely satisfied with your subscription to a Williams & Wilkins periodical, you are entitled to a full refund on all unmailed issues.

For customer service, call TOLL FREE:
1-800-638-6423
(from anywhere in the U.S., Canada, or Mexico)

International faxline: (410) 361-8048

Or write:
Subscription Fulfillment Department
Williams & Wilkins
351 W. Camden Street
Baltimore, MD 21201-2436

Williams & Wilkins
A WAVERLY COMPANY
Bromocriptine therapy was evaluated in anemia patients. No adverse effects were observed. Based on the results, it was concluded that bromocriptine may be useful in the treatment of anemia.

In conclusion, bromocriptine is a promising candidate for the treatment of anemia, especially in cases where other agents have failed. Further studies are recommended to confirm these findings and to determine the optimal dosage and duration of treatment.
INNOVATION
Through Microemulsion

- Neoral® demonstrates intrasubject variability of drug exposure (%CV) [measured by the area under the concentration-vs.-time curve] in renal transplant recipients of 9% to 21% compared to 19% to 26% for Sandimmune® (cyclosporine)

- Neoral provides increased bioavailability* with adverse events* comparable to those of Sandimmune when the dosage of the two drugs is adjusted to achieve the same cyclosporine blood trough concentrations

- Routine monitoring is required and dosage adjustments may be necessary in both de novo patients and maintenance patients converted from Sandimmune to Neoral®

- Neoral and Sandimmune are not bioequivalent and cannot be used interchangeably without physician supervision

- Neoral offers an important option for the prevention of organ rejection in renal, liver, and heart allogeneic transplant recipients

NEORAL®
cyclosporine capsules and oral solution for microemulsion

Reference

SANDOZ TRANSPLANT
A Division of Novartis Pharmaceuticals Corporation

Please see brief summary of prescribing information and boxed warning for Neoral on the adjacent page.
©1997 Novartis